Evaxion A/S (EVAX)

NASDAQ: EVAX · Real-Time Price · USD

5.60

-0.17 (-2.95%)

At close: Nov 4, 2025, 4:00 PM EST

5.77

+0.17 (3.04%)

After-hours: Nov 4, 2025, 7:43 PM EST

Evaxion Employees

Evaxion had 46 employees as of December 31, 2024. The number of employees decreased by 3 or -6.12% compared to the previous year.

Employees

46

Change (1Y)

-3

Growth (1Y)

-6.12%

Revenue / Employee

$69,043

Profits / Employee

-$260,304

Market Cap

35.37M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	46	-3	-6.12%
Dec 31, 2023	49	-14	-22.22%
Dec 31, 2022	63	2	3.28%
Dec 31, 2021	61	26	74.29%
Dec 31, 2020	35	-1	-2.78%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

EVAX News

1 day ago - Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate - GlobeNewsWire
4 days ago - Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire
4 days ago - Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire
5 days ago - Evaxion raises $7.2 million, extending cash runway to second half of 2027 - GlobeNewsWire
8 days ago - Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer - GlobeNewsWire
13 days ago - Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript - Seeking Alpha
18 days ago - Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 - GlobeNewsWire
22 days ago - Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 - GlobeNewsWire